2m 2m 2m 2m 2m 2m 2m
Neurocrine Biosc (NBIX)
NASDAQ
$164.78+$3.16 (+1.95%)
Price as of Jun 23, 2026 5:12 PM EDT- $16.3BMarket Cap
- 28.47%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Neurocrine Biosc (NBIX)
$164.78+$3.16 (+1.95%)
NBIX | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $161.62 | ||
Change | +$3.33 (+2.10%) | ||
Open | $161.17 | ||
High | $161.79 | ||
Low | $159.32 | ||
Previous Close | $158.29 | ||
Volume | 1,008,894 | ||
30-Day Average Volume | 1,209,478 | ||
1-Week Change | 1.32% | ||
1-Month Change | 3.14% | ||
1-Year Change | 28.47% | ||
3-Year Change | 65.17% | ||
5-Year Change | 58.03% | ||
Fundamentals | |||
Shares Outstanding | 100.5M | ||
Total Assets | $4.9B | ||
Market Cap | $16.3B | ||
Enterprise Value | $16.0B | ||
Period: QTR TTM FY | |||
Revenue | $811.0M | ||
Net Income | $197.9M | ||
Free Cash Flow | $136.7M | ||
EBIT | $246.8M | ||
EBITDA | $246.9M | ||
Net Working Capital | $1.6B | ||
EPS | $1.91 | ||
Enterprise Value/EBITDA | 65 | ||
Enterprise Value/Revenue | 20 | ||
P/B | 5 | ||
P/E | 85 | ||
PEG | 3 | ||
Price/Free Cash Flow | 119 | ||
Price/Operating Cash Flow | 111 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue